CLBT Stock Forecast & Price Target

Cellebrite DI is viewed positively because its new CEO is emphasizing better execution, sharper packaging, and disciplined forecasting while the company still sees substantial growth opportunities in public safety, defense, and intelligence. The business is also benefiting from strong demand in Defense & Intelligence, where ARR grew 25% year over year, while Genesis is gaining traction with more than half a dozen Q2 deals and ARR approaching $1M, suggesting new products can offset fading Inseyets migrations. Financially, the company posted gross profit of $112.1 million with an 85.5% gross margin and adjusted EBITDA of $31.8 million, and it continues to generate 30%-plus free cash flow margins on reset valuation metrics that look attractive versus peers.

Cellebrite DI is facing a fragile fundamental setup because roughly 90% of revenue comes from public-sector customers, including a high-teens percentage from U.S. federal, leaving results exposed to budget delays, shutdowns, and seasonal procurement patterns. The company’s Q2 ARR of $507.8 million missed consensus and the low end of guidance, while management cut CY26 ARR growth expectations from about 18.5% to 15.5% and lowered ARR guidance to $555 million, signaling slower demand and longer sales cycles. Beyond execution risk, competition and technology remain structural threats, since Cellebrite must keep pace with new hardware and OS changes while smartphone makers could patch vulnerabilities that underpin its core device-unlocking value proposition.